Skip to main content
Top
Published in: Endocrine 2/2021

01-02-2021 | Meta- Analysis

Effects of growth hormone on cognitive, motor, and behavioral development in Prader-Willi syndrome children: a meta-analysis of randomized controlled trials

Authors: Yunyun Luo, Zhoude Zheng, Yingying Yang, Xi Bai, Hongbo Yang, Huijuan Zhu, Hui Pan, Shi Chen

Published in: Endocrine | Issue 2/2021

Login to get access

Abstract

Purpose

The benefits of growth hormone (GH) therapy in Prader-Willi syndrome (PWS) children are well established, but there is still considerable controversy regarding whether GH treatment can improve cognitive, motor, and behavioral development in PWS children. The objectives of this meta-analysis were to quantitatively evaluate the effects of GH on cognitive, motor function, and behavioral development in PWS children.

Methods

Randomized controlled trials (RCTs) examining the effects of GH on cognitive, motor, and behavioral development in PWS children were identified by searching the MEDLINE, EMBASE, and Cochrane Library databases. Intervention effects were represented by Hedges’g and pooled to calculate effect sizes using a random-effects model.

Results

Ten relevant studies comprising data from 302 participants were finally included. We observed no significant difference in cognitive performance between the GH treatment group and the control group (p = 0.197). GH treatment was shown to remarkably improve motor development in PWS children compared with the control treatment (p < 0.001), with moderate positive treatment effects (Hedges’g [95% CI] = 0.71 [0.38, 1.03]). There were no significant differences between the GH group and the control group based on objective assessments of behavioral development (p = 0.53).

Conclusions

The meta-analysis suggested that GH treatment had a significantly positive effect on motor development, with moderate treatment effects in PWS children; however, there was no evidence of effects on cognitive or behavioral development.
Appendix
Available only for authorised users
Literature
1.
go back to reference N.E. Bakker, E.P. Siemensma, M. Van Rijn et al. Beneficial effect of growth hormone treatment on health-related quality of life in children with Prader-Willi syndrome: a randomized controlled trial and longitudinal study. Horm. Res. Paediatr. 84(4), 231–239 (2015)CrossRef N.E. Bakker, E.P. Siemensma, M. Van Rijn et al. Beneficial effect of growth hormone treatment on health-related quality of life in children with Prader-Willi syndrome: a randomized controlled trial and longitudinal study. Horm. Res. Paediatr. 84(4), 231–239 (2015)CrossRef
2.
go back to reference L. Reus, L.A. Van Vlimmeren, J.B. Staal et al. The effect of growth hormone treatment or physical training on motor performance in Prader-Willi syndrome: a systematic review. Neurosc. Biobehav. Rev. 36(8), 1817–1838 (2012)CrossRef L. Reus, L.A. Van Vlimmeren, J.B. Staal et al. The effect of growth hormone treatment or physical training on motor performance in Prader-Willi syndrome: a systematic review. Neurosc. Biobehav. Rev. 36(8), 1817–1838 (2012)CrossRef
3.
go back to reference G. Muscogiuri, G. Formoso, G. Pugliese et al. Prader- Willi syndrome: an uptodate on endocrine and metabolic complications. Rev. Endocr. Metab. Disord. 20(2), 239–250 (2019)CrossRef G. Muscogiuri, G. Formoso, G. Pugliese et al. Prader- Willi syndrome: an uptodate on endocrine and metabolic complications. Rev. Endocr. Metab. Disord. 20(2), 239–250 (2019)CrossRef
4.
go back to reference A.L. Carrel, S.E. Myers, B.Y. Whitman et al. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study. J. Clin. Endocrinol. Metab. 87(4), 1581–1585 (2002)CrossRef A.L. Carrel, S.E. Myers, B.Y. Whitman et al. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study. J. Clin. Endocrinol. Metab. 87(4), 1581–1585 (2002)CrossRef
5.
go back to reference K.S. Vogt, J.E. Emerick, Growth hormone therapy in adults with Prader-Willi syndrome. Diseases 3(2), 56–67 (2015)CrossRef K.S. Vogt, J.E. Emerick, Growth hormone therapy in adults with Prader-Willi syndrome. Diseases 3(2), 56–67 (2015)CrossRef
6.
go back to reference B. Whitman, A. Carrel, T. Bekx et al. Growth hormone improves body composition and motor development in infants with Prader-Willi syndrome after six months. J. Pediatr. Endocrinol. Metab. 17(4), 591–600 (2004)CrossRef B. Whitman, A. Carrel, T. Bekx et al. Growth hormone improves body composition and motor development in infants with Prader-Willi syndrome after six months. J. Pediatr. Endocrinol. Metab. 17(4), 591–600 (2004)CrossRef
7.
go back to reference E.P. Siemensma, L.I.N.D. Tummers-De, R.F. Van Wijngaarden, D.A. Festen et al. Beneficial effects of growth hormone treatment on cognition in children with Prader-Willi syndrome: a randomized controlled trial and longitudinal study. J. Clin. Endocrinol. Metab. 97(7), 2307–2314 (2012)CrossRef E.P. Siemensma, L.I.N.D. Tummers-De, R.F. Van Wijngaarden, D.A. Festen et al. Beneficial effects of growth hormone treatment on cognition in children with Prader-Willi syndrome: a randomized controlled trial and longitudinal study. J. Clin. Endocrinol. Metab. 97(7), 2307–2314 (2012)CrossRef
8.
go back to reference E.M. Dykens, E. Roof, H. Hunt-Hawkins, Cognitive and adaptive advantages of growth hormone treatment in children with Prader-Willi syndrome. J. Child. Psychol. Psychiatry. 58(1), 64–74 (2017)CrossRef E.M. Dykens, E. Roof, H. Hunt-Hawkins, Cognitive and adaptive advantages of growth hormone treatment in children with Prader-Willi syndrome. J. Child. Psychol. Psychiatry. 58(1), 64–74 (2017)CrossRef
9.
go back to reference A.M. Haqq, D.D. Stadler, R.H. Jackson et al. Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 88(5), 2206–2212 (2003)CrossRef A.M. Haqq, D.D. Stadler, R.H. Jackson et al. Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 88(5), 2206–2212 (2003)CrossRef
10.
go back to reference B. Bohm, E.M. Ritzen, A.C. Lindgren, Growth hormone treatment improves vitality and behavioural issues in children with Prader-Willi syndrome. Acta Paediatr. 104(1), 59–67 (2015)CrossRef B. Bohm, E.M. Ritzen, A.C. Lindgren, Growth hormone treatment improves vitality and behavioural issues in children with Prader-Willi syndrome. Acta Paediatr. 104(1), 59–67 (2015)CrossRef
11.
go back to reference S.E. Myers, B.Y. Whitman, A.L. Carrel et al. Two years of growth hormone therapy in young children with Prader-Willi syndrome: physical and neurodevelopmental benefits. Am. J. Med. Genet. A 143a(5), 443–448 (2007)CrossRef S.E. Myers, B.Y. Whitman, A.L. Carrel et al. Two years of growth hormone therapy in young children with Prader-Willi syndrome: physical and neurodevelopmental benefits. Am. J. Med. Genet. A 143a(5), 443–448 (2007)CrossRef
12.
go back to reference S.H. Donze, L. Damen, E.F. Mahabier et al. Improved mental and motor development during 3 years of GH treatment in very young children with Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 103(10), 3714–3719 (2018)CrossRef S.H. Donze, L. Damen, E.F. Mahabier et al. Improved mental and motor development during 3 years of GH treatment in very young children with Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 103(10), 3714–3719 (2018)CrossRef
13.
go back to reference M.G. Butler, N.A. Matthews, N. Patel et al. Impact of genetic subtypes of Prader-Willi syndrome with growth hormone therapy on intelligence and body mass index. Am. J. Med. Genet. A 179(9), 1826–1835 (2019)PubMedPubMedCentral M.G. Butler, N.A. Matthews, N. Patel et al. Impact of genetic subtypes of Prader-Willi syndrome with growth hormone therapy on intelligence and body mass index. Am. J. Med. Genet. A 179(9), 1826–1835 (2019)PubMedPubMedCentral
14.
go back to reference S.T. Lo, E.P. Siemensma, D.A. Festen et al. Behavior in children with Prader-Willi syndrome before and during growth hormone treatment: a randomized controlled trial and 8-year longitudinal study. Eur. Child. Adolesc. Psychiatry 24(9), 1091–1101 (2015)CrossRef S.T. Lo, E.P. Siemensma, D.A. Festen et al. Behavior in children with Prader-Willi syndrome before and during growth hormone treatment: a randomized controlled trial and 8-year longitudinal study. Eur. Child. Adolesc. Psychiatry 24(9), 1091–1101 (2015)CrossRef
15.
go back to reference A.L. Carrel, S.E. Myers, B.Y. Whitman et al. Long-term growth hormone therapy changes the natural history of body composition and motor function in children with prader-willi syndrome. J. Clin. Endocrinol. Metab. 95(3), 1131–1136 (2010)CrossRef A.L. Carrel, S.E. Myers, B.Y. Whitman et al. Long-term growth hormone therapy changes the natural history of body composition and motor function in children with prader-willi syndrome. J. Clin. Endocrinol. Metab. 95(3), 1131–1136 (2010)CrossRef
16.
go back to reference R.J. Kuppens, E.F. Mahabier, N.E. Bakker et al. Effect of cessation of GH treatment on cognition during transition phase in Prader-Willi syndrome: results of a 2-year crossover GH trial. Orphanet. J. Rare Dis. 11(1), 153 (2016)CrossRef R.J. Kuppens, E.F. Mahabier, N.E. Bakker et al. Effect of cessation of GH treatment on cognition during transition phase in Prader-Willi syndrome: results of a 2-year crossover GH trial. Orphanet. J. Rare Dis. 11(1), 153 (2016)CrossRef
17.
go back to reference A.L. Carrel, S.E. Myers, B.Y. Whitman et al. Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: a controlled study. J. Pediatr. 134(2), 215–221 (1999)CrossRef A.L. Carrel, S.E. Myers, B.Y. Whitman et al. Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: a controlled study. J. Pediatr. 134(2), 215–221 (1999)CrossRef
18.
go back to reference A.L. Carrel, V. Moerchen, S.E. Myers et al. Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome. J. Pediatr. 145(6), 744–749 (2004)CrossRef A.L. Carrel, V. Moerchen, S.E. Myers et al. Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome. J. Pediatr. 145(6), 744–749 (2004)CrossRef
19.
go back to reference L.E. Oberlin, A.M. Waiwood, T.B. Cumming et al. Effects of physical activity on poststroke cognitive function: a meta-analysis of randomized controlle trials. Stroke 48(11), 3093–3100 (2017)CrossRef L.E. Oberlin, A.M. Waiwood, T.B. Cumming et al. Effects of physical activity on poststroke cognitive function: a meta-analysis of randomized controlle trials. Stroke 48(11), 3093–3100 (2017)CrossRef
20.
go back to reference M.G. Falleti, P. Maruff, P. Burman et al. The effects of growth hormone (GH) deficiency and GH replacement on cognitive performance in adults: a meta-analysis of the current literature. Psychoneuroendocrinology 31(6), 681–691 (2006)CrossRef M.G. Falleti, P. Maruff, P. Burman et al. The effects of growth hormone (GH) deficiency and GH replacement on cognitive performance in adults: a meta-analysis of the current literature. Psychoneuroendocrinology 31(6), 681–691 (2006)CrossRef
21.
go back to reference A.J. Osborn, R.M. Roberts, J.L. Mathias et al. Cognitive, behavioral and psychological functioning in children with metopic synostosis: a meta-analysis examining the impact of surgical status. Child Neuropsychol. 25(2), 263–277 (2019)CrossRef A.J. Osborn, R.M. Roberts, J.L. Mathias et al. Cognitive, behavioral and psychological functioning in children with metopic synostosis: a meta-analysis examining the impact of surgical status. Child Neuropsychol. 25(2), 263–277 (2019)CrossRef
22.
go back to reference J. Cohen. Statistical Power Analysis for the Behavioral Sciences. Rev. edn. (Academic Press, New York, NY, 1977) J. Cohen. Statistical Power Analysis for the Behavioral Sciences. Rev. edn. (Academic Press, New York, NY, 1977)
23.
go back to reference X. Wan, W. Wang, J. Liu et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med. Res. Methodol. 14, 135 (2014)CrossRef X. Wan, W. Wang, J. Liu et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med. Res. Methodol. 14, 135 (2014)CrossRef
24.
go back to reference 刘海宁, 吴昊, 姚灿, et al. Meta分析中连续性数据的深度提取方法. 中国循证医学杂志. 17(1), 117–121 (2017). 刘海宁, 吴昊, 姚灿, et al. Meta分析中连续性数据的深度提取方法. 中国循证医学杂志. 17(1), 117–121 (2017).
25.
go back to reference D.A. Festen, M. Wevers, A.C. Lindgren et al. Mental and motor development before and during growth hormone treatment in infants and toddlers with Prader-Willi syndrome. Clin. Endocrinol. 68(6), 919–925 (2008)CrossRef D.A. Festen, M. Wevers, A.C. Lindgren et al. Mental and motor development before and during growth hormone treatment in infants and toddlers with Prader-Willi syndrome. Clin. Endocrinol. 68(6), 919–925 (2008)CrossRef
26.
go back to reference R. Sanchez-Ortiga, A. Klibanski, N.A. Tritos, Effects of recombinant human growth hormone therapy in adults with Prader-Willi syndrome: a meta-analysis. Clin. Endocrinol. 77(1), 86–93 (2012)CrossRef R. Sanchez-Ortiga, A. Klibanski, N.A. Tritos, Effects of recombinant human growth hormone therapy in adults with Prader-Willi syndrome: a meta-analysis. Clin. Endocrinol. 77(1), 86–93 (2012)CrossRef
27.
go back to reference A. Yang, J.H. Choi, Y.B. Sohn et al. Effects of recombinant human growth hormone treatment on growth, body composition, and safety in infants or toddlers with Prader-Willi syndrome: a randomized, active-controlled trial. Orphanet. J. Rare Dis. 14, 216 (2019)CrossRef A. Yang, J.H. Choi, Y.B. Sohn et al. Effects of recombinant human growth hormone treatment on growth, body composition, and safety in infants or toddlers with Prader-Willi syndrome: a randomized, active-controlled trial. Orphanet. J. Rare Dis. 14, 216 (2019)CrossRef
28.
go back to reference B.A. Kinney, K.T. Coschigano, J.J. Kopchick et al. Evidence that age-induced decline in memory retention is delayed in growth hormone resistant GH-R-KO (Laron) mice. Physiol. Behav. 72(5), 653–660 (2001)CrossRef B.A. Kinney, K.T. Coschigano, J.J. Kopchick et al. Evidence that age-induced decline in memory retention is delayed in growth hormone resistant GH-R-KO (Laron) mice. Physiol. Behav. 72(5), 653–660 (2001)CrossRef
29.
go back to reference K. Nashiro, J. Guevara-Aguirre, M.N. Braskie et al. Brain structure and function associated with younger adults in growth hormone receptor-deficient humans. J. Neurosci. 37(7), 1696–1707 (2017)CrossRef K. Nashiro, J. Guevara-Aguirre, M.N. Braskie et al. Brain structure and function associated with younger adults in growth hormone receptor-deficient humans. J. Neurosci. 37(7), 1696–1707 (2017)CrossRef
30.
go back to reference F. Lupu, J.D. Terwilliger, K. Lee et al. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev. Biol. 229(1), 141–162 (2001)CrossRef F. Lupu, J.D. Terwilliger, K. Lee et al. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev. Biol. 229(1), 141–162 (2001)CrossRef
31.
go back to reference L.Y. Sun, K. Al-Regaiey, M.M. Masternak et al. Local expression of GH and IGF-1 in the hippocampus of GH-deficient long-lived mice. Neurobiol. Aging 26(6), 929–937 (2005)CrossRef L.Y. Sun, K. Al-Regaiey, M.M. Masternak et al. Local expression of GH and IGF-1 in the hippocampus of GH-deficient long-lived mice. Neurobiol. Aging 26(6), 929–937 (2005)CrossRef
32.
go back to reference J.Y. Chung, H.J. Kim, M. Kim, The protective effect of growth hormone on Cu/Zn superoxide dismutase-mutant motor neurons. BMC Neurosci. 16(1), 1 (2015)CrossRef J.Y. Chung, H.J. Kim, M. Kim, The protective effect of growth hormone on Cu/Zn superoxide dismutase-mutant motor neurons. BMC Neurosci. 16(1), 1 (2015)CrossRef
33.
go back to reference D. Mackenzie, F. Shamim, K. Mongeon et al. Human growth hormone increases SMN expression and survival in severe spinal muscular atrophy mouse model. J Neuromuscul Dis 1(1), 65–74 (2014)CrossRef D. Mackenzie, F. Shamim, K. Mongeon et al. Human growth hormone increases SMN expression and survival in severe spinal muscular atrophy mouse model. J Neuromuscul Dis 1(1), 65–74 (2014)CrossRef
34.
go back to reference S. Sanchez-Bezanilla, N.D. Åberg, P. Crock et al. Growth hormone promotes motor function after experimental stroke and enhances recovery-promoting mechanisms within the peri-infarct area. Int. J. Mol. Sci. 21(2), 606 (2020) S. Sanchez-Bezanilla, N.D. Åberg, P. Crock et al. Growth hormone promotes motor function after experimental stroke and enhances recovery-promoting mechanisms within the peri-infarct area. Int. J. Mol. Sci. 21(2), 606 (2020)
35.
go back to reference M. Heredia, A. Fuente, J. Criado et al. Early growth hormone (GH) treatment promotes relevant motor functional improvement after severe frontal cortex lesion in adult rats. Behav. Brain Res. 247, 48–58 (2013)CrossRef M. Heredia, A. Fuente, J. Criado et al. Early growth hormone (GH) treatment promotes relevant motor functional improvement after severe frontal cortex lesion in adult rats. Behav. Brain Res. 247, 48–58 (2013)CrossRef
Metadata
Title
Effects of growth hormone on cognitive, motor, and behavioral development in Prader-Willi syndrome children: a meta-analysis of randomized controlled trials
Authors
Yunyun Luo
Zhoude Zheng
Yingying Yang
Xi Bai
Hongbo Yang
Huijuan Zhu
Hui Pan
Shi Chen
Publication date
01-02-2021
Publisher
Springer US
Published in
Endocrine / Issue 2/2021
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02547-3

Other articles of this Issue 2/2021

Endocrine 2/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.